Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes

Ferrua, 2017, Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug, Hum. Gene Ther., 28, 972, 10.1089/hum.2017.175 June, 2018, CAR T cell immunotherapy for human cancer, Science, 359, 1361, 10.1126/science.aar6711 Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003 Robbins, 2015, A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response, Clin. Cancer Res., 21, 1019, 10.1158/1078-0432.CCR-14-2708 Rapoport, 2015, NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma, Nat. Med., 21, 914, 10.1038/nm.3910 Morgan, 2013, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy, J. Immunother., 36, 133, 10.1097/CJI.0b013e3182829903 Karpanen, 2015, T-cell receptor gene therapy--ready to go viral?, Mol. Oncol., 9, 2019, 10.1016/j.molonc.2015.10.006 Saudemont, 2018, Current Status of Gene Engineering Cell Therapeutics, Front. Immunol., 9, 153, 10.3389/fimmu.2018.00153 Maude, 2018, Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N. Engl. J. Med., 378, 439, 10.1056/NEJMoa1709866 Neelapu, 2017, Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447 Hartmann, 2017, Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts, EMBO Mol. Med., 9, 1183, 10.15252/emmm.201607485 MacDonald, 2016, Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor, J. Clin. Invest., 126, 1413, 10.1172/JCI82771 Skuljec, 2017, Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma, Front. Immunol., 8, 1125, 10.3389/fimmu.2017.01125 Yoon, 2017, FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII, Blood, 129, 238, 10.1182/blood-2016-07-727834 Fransson, 2012, CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery, J. Neuroinflammation, 9, 112, 10.1186/1742-2094-9-112 Ellebrecht, 2016, Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease, Science, 353, 179, 10.1126/science.aaf6756 Zhang, 2018, Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells, J. Immunol., 201, 1434, 10.4049/jimmunol.1701800 Siddiqui, 2016, Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient, J. Immunother. Cancer, 4, 21, 10.1186/s40425-016-0125-1 Zhao, 2017, CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes, Oncotarget, 9, 5208, 10.18632/oncotarget.23730 Liu, 2016, A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors, Cancer Res., 76, 1578, 10.1158/0008-5472.CAN-15-2524 Leen, 2014, Reversal of tumor immune inhibition using a chimeric cytokine receptor, Mol. Ther., 22, 1211, 10.1038/mt.2014.47 Mohammed, 2017, Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer, Mol. Ther., 25, 249, 10.1016/j.ymthe.2016.10.016 Kunert, 2017, Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors, OncoImmunology, 7, e1378842, 10.1080/2162402X.2017.1378842 Peterson, 2018, Cell and Gene Therapy for HIV Cure, Curr. Top. Microbiol. Immunol., 417, 211 Rogers, 2017, Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases, Hematol. Oncol. Clin. North Am., 31, 883, 10.1016/j.hoc.2017.06.008 Levine, 2006, Gene transfer in humans using a conditionally replicating lentiviral vector, Proc. Natl. Acad. Sci. USA, 103, 17372, 10.1073/pnas.0608138103 Egelhofer, 2004, Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides, J. Virol., 78, 568, 10.1128/JVI.78.2.568-575.2004 Perica, 2015, Adoptive T cell immunotherapy for cancer, Rambam Maimonides Med. J., 6, e0004, 10.5041/RMMJ.10179 Herrera-Carrillo, 2016, Attacking HIV-1 RNA versus DNA by sequence-specific approaches: RNAi versus CRISPR-Cas, Biochem. Soc. Trans., 44, 1355, 10.1042/BST20160060 Lee, 2008, Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses, Immunology, 125, 229, 10.1111/j.1365-2567.2008.02833.x Stripecke, 2000, Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses, Blood, 96, 1317, 10.1182/blood.V96.4.1317 Melo, 2002, Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases, J. Immunol., 168, 4788, 10.4049/jimmunol.168.9.4788 Wang, 2014, Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells, Mol. Ther., 22, 1139, 10.1038/mt.2014.43 Luo, 2009, Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes, Blood, 113, 1422, 10.1182/blood-2008-09-177139 Hur, 2012, Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice, Blood, 120, 4571, 10.1182/blood-2012-04-422303 Joseph, 2010, Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody, J. Virol., 84, 6645, 10.1128/JVI.02339-09 Fusil, 2015, A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status, Mol. Ther., 23, 1734, 10.1038/mt.2015.148 Hung, 2018, Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells, Mol. Ther., 26, 456, 10.1016/j.ymthe.2017.11.012 Levy, 2016, Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc-/- mice, J. Thromb. Haemost., 14, 2478, 10.1111/jth.13520 Amirache, 2014, Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor, Blood, 123, 1422, 10.1182/blood-2013-11-540641 Frecha, 2010, Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy, Mol. Ther., 18, 1748, 10.1038/mt.2010.178 Xu, 2014, Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15, Blood, 123, 3750, 10.1182/blood-2014-01-552174 Casucci, 2018, Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene, Front. Immunol., 9, 507, 10.3389/fimmu.2018.00507 Golubovskaya, 2016, Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy, Cancers (Basel), 8, 36, 10.3390/cancers8030036 Berger, 2008, Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates, J. Clin. Invest., 118, 294, 10.1172/JCI32103 Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood, 118, 6050, 10.1182/blood-2011-05-354449 Fraietta, 2018, Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, Nat. Med., 24, 563, 10.1038/s41591-018-0010-1 Wang, 2016, Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL, Blood, 127, 2980, 10.1182/blood-2015-12-686725 Wu, 2013, Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy, Cancer Lett., 339, 195, 10.1016/j.canlet.2013.06.009 Frecha, 2008, Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins, Blood, 112, 4843, 10.1182/blood-2008-05-155945 Frecha, 2011, Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors, J. Virol., 85, 5975, 10.1128/JVI.00324-11 Zhou, 2011, Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM, Virology, 413, 149, 10.1016/j.virol.2011.02.010 Girard-Gagnepain, 2014, Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs, Blood, 124, 1221, 10.1182/blood-2014-02-558163 Powell, 2015, Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy, Discov. Med., 19, 49 Marodon, 2003, Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene, Blood, 101, 3416, 10.1182/blood-2002-02-0578 Zhou, 2012, T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing, Blood, 120, 4334, 10.1182/blood-2012-02-412973 Zhou, 2015, Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors, J. Immunol., 195, 2493, 10.4049/jimmunol.1500956 Kneissl, 2013, CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes, PLoS ONE, 8, e79047, 10.1371/journal.pone.0079047 Cosset, 1995, Retroviral retargeting by envelopes expressing an N-terminal binding domain, J. Virol., 69, 6314, 10.1128/JVI.69.10.6314-6322.1995 Höfig, 2014, Systematic improvement of lentivirus transduction protocols by antibody fragments fused to VSV-G as envelope glycoprotein, Biomaterials, 35, 4204, 10.1016/j.biomaterials.2014.01.051 Goyvaerts, 2013, Targeting of human antigen-presenting cell subsets, J. Virol., 87, 11304, 10.1128/JVI.01498-13 Goyvaerts, 2017, Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery, Gene Ther., 24, 370, 10.1038/gt.2017.30 Morizono, 2005, Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection, Nat. Med., 11, 346, 10.1038/nm1192 Nakamura, 2005, Rescue and propagation of fully retargeted oncolytic measles viruses, Nat. Biotechnol., 23, 209, 10.1038/nbt1060 Springfeld, 2005, Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism, J. Virol., 79, 10155, 10.1128/JVI.79.16.10155-10163.2005 Bender, 2016, Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment, PLoS Pathog., 12, e1005641, 10.1371/journal.ppat.1005641 Li, 2010, Structural changes of envelope proteins during alphavirus fusion, Nature, 468, 705, 10.1038/nature09546 Liang, 2009, Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway, J. Virol., 83, 13026, 10.1128/JVI.01530-09 Rasbach, 2013, The receptor attachment function of measles virus hemagglutinin can be replaced with an autonomous protein that binds Her2/neu while maintaining its fusion-helper function, J. Virol., 87, 6246, 10.1128/JVI.03298-12 Yang, 2006, Targeting lentiviral vectors to specific cell types in vivo, Proc. Natl. Acad. Sci. USA, 103, 11479, 10.1073/pnas.0604993103 Buchholz, 2015, Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene Delivery, Trends Biotechnol., 33, 777, 10.1016/j.tibtech.2015.09.008 Lévy, 2015, Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells, Curr. Opin. Pharmacol., 24, 79, 10.1016/j.coph.2015.08.003 Tiller, 2015, Advances in Antibody Design, Annu. Rev. Biomed. Eng., 17, 191, 10.1146/annurev-bioeng-071114-040733 Frenzel, 2016, Phage display-derived human antibodies in clinical development and therapy, MAbs, 8, 1177, 10.1080/19420862.2016.1212149 Friedel, 2015, Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain Fv, Protein Eng. Des. Sel., 28, 93, 10.1093/protein/gzv005 Goyvaerts, 2012, Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells, Gene Ther., 19, 1133, 10.1038/gt.2011.206 Plückthun, 2015, Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy, Annu. Rev. Pharmacol. Toxicol., 55, 489, 10.1146/annurev-pharmtox-010611-134654 Münch, 2011, DARPins: an efficient targeting domain for lentiviral vectors, Mol. Ther., 19, 686, 10.1038/mt.2010.298 Münch, 2013, Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer, Mol. Ther., 21, 109, 10.1038/mt.2012.186 Hartmann, 2018, A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors, Mol. Ther. Methods Clin. Dev., 10, 128, 10.1016/j.omtm.2018.07.001 Verhoeyen, 2003, IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes, Blood, 101, 2167, 10.1182/blood-2002-07-2224 Leandro, 2013, B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies, Arthritis Res. Ther., 15, S3, 10.1186/ar3908 Wang, 2012, CD19: a biomarker for B cell development, lymphoma diagnosis and therapy, Exp. Hematol. Oncol., 1, 36, 10.1186/2162-3619-1-36 Harwood, 2008, New insights into the early molecular events underlying B cell activation, Immunity, 28, 609, 10.1016/j.immuni.2008.04.007 Funke, 2008, Targeted cell entry of lentiviral vectors, Mol. Ther., 16, 1427, 10.1038/mt.2008.128 Enkirch, 2013, Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins, Gene Ther., 20, 16, 10.1038/gt.2011.209 Wang, 2017, Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells, Mol. Ther. Methods Clin. Dev., 5, 76, 10.1016/j.omtm.2017.03.005 Buchholz, 2009, Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer?, Trends Biotechnol., 27, 259, 10.1016/j.tibtech.2009.02.002 Maurice, 2002, Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide, Blood, 99, 2342, 10.1182/blood.V99.7.2342 Yang, 2009, Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule, Pharm. Res., 26, 1432, 10.1007/s11095-009-9853-y Zhou, 2013, Cell type specific gene delivery by lentiviral vectors: New options in immunotherapy, OncoImmunology, 2, e22566, 10.4161/onci.22566 Jardine, 2013, Rapid detection of dendritic cell and monocyte disorders using CD4 as a lineage marker of the human peripheral blood antigen-presenting cell compartment, Front. Immunol., 4, 495, 10.3389/fimmu.2013.00495 Shortman, 2010, The CD8+ dendritic cell subset, Immunol. Rev., 234, 18, 10.1111/j.0105-2896.2009.00870.x Bonneville, 2002, CD8: from coreceptor to comodulator, Nat. Immunol., 3, 12, 10.1038/ni0102-12 Walsh, 2017, Humanized Mouse Models of Clinical Disease, Annu. Rev. Pathol., 12, 187, 10.1146/annurev-pathol-052016-100332 Gélinas, 2018, Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature, Microbiol. Mol. Biol. Rev., 82, 10.1128/MMBR.00051-17 Mackall, 2011, Harnessing the biology of IL-7 for therapeutic application, Nat. Rev. Immunol., 11, 330, 10.1038/nri2970 Pfeiffer, 2018, In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome, EMBO Mol. Med., 10.15252/emmm.201809158 Hay, 2017, Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy, Blood, 130, 2295, 10.1182/blood-2017-06-793141 Glienke, 2015, Advantages and applications of CAR-expressing natural killer cells, Front. Pharmacol., 6, 21, 10.3389/fphar.2015.00021 Spragg, 2016, Cell and gene therapy strategies to eradicate HIV reservoirs, Curr. Opin. HIV AIDS, 11, 442, 10.1097/COH.0000000000000284 Smith, 2017, In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers, Nat. Nanotechnol., 12, 813, 10.1038/nnano.2017.57 Pollack, 2017, First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient, J. Immunother., 40, 302, 10.1097/CJI.0000000000000183 Verhoeyen, 2005, Novel lentiviral vectors displaying “early-acting cytokines” selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells, Blood, 106, 3386, 10.1182/blood-2004-12-4736 Morizono, 2001, Antibody-directed targeting of retroviral vectors via cell surface antigens, J. Virol., 75, 8016, 10.1128/JVI.75.17.8016-8020.2001 Ziegler, 2008, Targeting lentiviral vectors to antigen-specific immunoglobulins, Hum. Gene Ther., 19, 861, 10.1089/hum.2007.149 Yang, 2008, Engineered lentivector targeting of dendritic cells for in vivo immunization, Nat. Biotechnol., 26, 326, 10.1038/nbt1390 Liang, 2009, Targeted transduction of CD34+ hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells, J. Gene Med., 11, 185, 10.1002/jgm.1290 Froelich, 2009, Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule, Biotechnol. Bioeng., 104, 206, 10.1002/bit.22378 Lafitte, 2012, In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens, Mol. Cancer, 11, 81, 10.1186/1476-4598-11-81 Anliker, 2010, Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors, Nat. Methods, 7, 929, 10.1038/nmeth.1514 Bayin, 2018, Selective Targeting of CD133-Expressing Glioblastoma Stem Cells Using Lentiviral Vectors, Methods Mol. Biol., 1741, 91, 10.1007/978-1-4939-7659-1_7 Ou, 2012, Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13, Hum. Gene Ther. Methods, 23, 137, 10.1089/hgtb.2012.054